Comparison of CT and PET/CT for biopsy guidance in oncological patients
| Autor: | Juliano Julio Cerci, Mateos Bogoni, João V. Vitola, Stefano Fanti, Rodrigo Cerci, Carlos Pereira, Cassiano Krauzer, Danielle Giacometti Sakamoto, Elena Tabacchi, Dominique Delbeke |
|---|---|
| Přispěvatelé: | Cerci JJ, Tabacchi E, Bogoni M, Delbeke D, Pereira CC, Cerci RJ, Krauzer C, Sakamoto DG, Fanti S, Vitola JV. |
| Rok vydání: | 2017 |
| Předmět: |
Image-Guided Biopsy
Male medicine.medical_specialty Percutaneous 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Fluorodeoxyglucose F18 Neoplasms Positron Emission Tomography Computed Tomography Biopsy Humans Medicine Radiology Nuclear Medicine and imaging Aged Cancer PET-CT medicine.diagnostic_test CT-guided biopsy business.industry Biological Transport PET/CT-guided biopsy Histology General Medicine Middle Aged medicine.disease FDG PET/CT 030220 oncology & carcinogenesis Orthopedic surgery Feasibility Studies Female Radiology business Nuclear medicine Complication |
| Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging. 44:1269-1274 |
| ISSN: | 1619-7089 1619-7070 |
| Popis: | PURPOSE: To compare FDG PET/CT and CT for the guidance of percutaneous biopsies with histological confirmation of lesions. METHODS: We prospectively evaluated 323 patients of whom 181 underwent FDG PET/CT-guided biopsy (total 188 biopsies) and 142 underwent CT-guided biopsy (total 146 biopsies). Biopsies were performed using the same PET/CT scanner with a fluoroscopic imaging system. Technical feasibility, clinical success and complication rates in the two groups were evaluated. RESULTS: Of the 188 biopsies with PET/CT guidance, 182 (96.8%) were successful with conclusive tissue samples obtained and of the 146 biopsies with CT guidance, 137 (93.8%) were successful. Therefore, 6 of 188 biopsies (3.1%) with PET/CT guidance and 9 of 146 (6.1%) with CT guidance were inconclusive (p = 0.19). Due to inconclusive histological results, 4 of the 188 lesions (2.1%) were rebiopsied with PET/CT guidance and 3 of 146 lesions (2.0%) were rebiopsied with CT guidance. Histology demonstrated that 142 of 188 lesions (75.5%) were malignant, and 40 (21.2%) were benign in the PET/CT-guided group, while 89 of 146 lesions (60.9%) were malignant and 48 (32.8%) were benign in the CT-guided group (p = 0.004 and 0.01, respectively). Patients with a histological diagnosis of benign lesion had no recurrence of disease with a minimum of 6 months follow-up. Of the 188 PET/CT-guided biopsies, 6 (3.1%) were repeat biopsies due to a previous nondiagnostic CT-guided biopsy performed in a different diagnostic centre. The interval between the two biopsies was less than a month in all cases. Histology revealed five malignant lesions and one benign lesion among these. The complication rate in the PET/CT-guided biopsy group was 12.7% (24 of 188), while in the CT-guided group, was 9.5% (14 of 146, p = 0.26). Therefore, there was no significant difference in complication rates between PET/CT and CT guidance. CONCLUSION: PET/CT-guided biopsy is already known to be a feasible and accurate method in the diagnostic work-up of suspected malignant lesions. This prospective analysis of a large number of patients demonstrated the feasibility and advantages of using PET/CT as the imaging method of choice for biopsy guidance, especially where FDG-avid foci do not show corresponding lesions on the CT scan. There were no significant differences in the ability to obtain a diagnostic specimen or in the complication rates between PET/CT and CT guidance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|